New Data on Connecticut Cannabis Sales
Recreational cannabis was approved in the state in June 2021, sales began at the beginning of 2023, and medical cannabis has been legal since 2012.
In a statement (1) dated July 10, the Connecticut Department of Consumer Protection released data concerning sales of cannabis for recreational and medical purposes as collected through its Seed-to-Sale Tracking System.
In the month of June, recreational cannabis sales totaled $12.5 million (1). When combined with the $11.3 million in sales for medical purposes, the total amount of cannabis sales last month in the state totaled close to $24 million (1). In comparison, recreational sales and medical sales for January 2023 totaled $5.1 million and $8 million respectively (1). The statement did note that medical cannabis patients do not pay taxes on their products (1).
Also included was data on the types of products purchased. “In the first six months of sales, 53 percent of sales were usable cannabis, or flower, while vapes made up 25 percent of sales,” the statement also explained (1) “Edible products represented 10 percent of sales.”
The statement also noted that medical cannabis sales in the state were not required to be tracked prior to January 10, 2023 (1).
References
- Consumer Protection releases June cannabis sales data https://portal.ct.gov/DCP/News-Releases-from-the-Department-of-Consumer-Protection/2023-News-Releases/Consumer-Protection-Releases-June-Cannabis-Sales-Data (accessed Jul 12, 2023).
- Connecticut: Medicinal marijuana legalization measure signed into law https://norml.org/news/2012/06/07/connecticut-medicinal-marijuana-legalization-measure-signed-into-law/ (accessed Jul 12, 2023).
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.
